is knowledgeable about

Bio material
12 RCC patients

Homo sapiens
7 HIV patients

Homo sapiens
9 patients with B-cell CLL

Homo sapiens
CD28+ T cells in tumor lymphocytic infiltrates

T cell
CD40L-encoding RNA

ribonucleic acids
CLL-DCV01

vaccine
DC vaccine

vaccine
DC-based vaccine

vaccine
IFN alpha

interferon alpha
Immature DC

immature dendritic cell
Matured DC

mature dendritic cell
PGE2

Prostaglandin E2
PME-CD40L DC

dendritic cell
RCC patients

Homo sapiens
TNF alpha

Tumor necrosis factor alpha
Tumor RNA

ribonucleic acids
show more (14) show less
Protocols
Improving the efficacy of DC vaccines - ArcelisTM

Laboratory protocol
Phase 1 Protocol for phase 1 HIV clinical study

Clinical protocol
Phase 2a Protocol for the Phase 2 HIV study

Clinical protocol
Standardization of DC generation

Laboratory protocol
show more (2) show less
Tools
Arcelis therapeutic platform

device
Automated closed system

device
Datasets
Clinical trials of DC-based immunotherapy for RCC

clinical study dataset
Immunomonitoring, e.g. effector memory T cells

clinical study dataset
Optimisation of maturation stimuli for GMP-grad...

preclinical study dataset
Phase 1 HIV clinical study

clinical study dataset
Phase 1/2 CLL clinical study

clinical study dataset
RCC phase 2 trial

clinical study dataset
show more (4) show less

Persons > Charles Nicolette

Avatar_empty

Charles Nicolette

Affiliation

Scientific responsible

Argos Therapeutics, Inc.

DC-THERA Partner

Contact Information

download vcard

Phone	+1 (919) 287-6347
Fax	+1 (919) 287-6301
Email	cnicolette@argostherapeutics.com
Web	http://www.argostherapeutics.com/management_team.html#charles
Address	4233 Technology Drive Durham (North Carolina) USA

[ RDF

] [ RelFinder

]